53.04 USD
▼-0.96-1.78%
盘后 53.81 +1.44%
2026-09-15
市值
$7.52B
市盈率
19.16
EPS
2.77
股息率
—
52 周区间
26.76 – 59.30
成交量
1.76M
Beta
1.66
目标价
69.71
52W 低 26.7652W 高 59.30
价格走势
公司简介
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Ublituximab ...